To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

September 30, 2009

Conditions

Nasopharyngeal Cancer

Interventions

DRUG

Zometa (zoledronic acid)

Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily

Trial Locations (1)

Li Zhang, Guangzhou